Stephen K. Brannan - Concepedia

Author

Stephen K. Brannan

The University of Texas Southwestern Medical Center ORCID

Also Known As

Brannan, Stephen K., S K Brannan, S. BRANNAN, S. Brannan, S.K. Brannan, Stephen Brannan, Stephen C Brannan, Stephen K Brannan, Stephen K. Brannan

Publications

8.4K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Southwestern Medical Center Indiana University – Purdue University Indianapolis The University of Texas Health Science Center at San Antonio Takeda (United States)Indiana University School of Medicine

About

Stephen K. Brannan is an author at The University of Texas Southwestern Medical Center specializing in medicine, psychiatry, and social sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	3.3K
2	Social Sciences	12	13	3.2K
3	Health Sciences	1	1	35
4	Nursing	1	1	39
5	Public Health	1	1	39

Stephen K. Brannan

Publications

6.9K

Citations

H-Index

Page 1

	Year	Citations
Reciprocal Limbic-Cortical Function and Negative Mood: Converging PET Findings in Depression and Normal Sadness Helen S. Mayberg, Mario Liotti, Stephen K. Brannan, American Journal of Psychiatry	1999	2.4K
Cingulate function in depression Helen S. Mayberg, Stephen K. Brannan, Roderick K. Mahurin, Neuroreport NeuropsychologyPsychotropic MedicationPsychopharmacologySocial SciencesPsychology	1997	1K
Seminars in Clinical Neuropsychiatry Stephen K. Brannan JAMA NeuropsychologyNeuropsychiatric DisordersDisabilityClinical NeurologyNeuropsychiatry	1997	436
Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study A. John Rush, Harold A. Sackeïm, Lauren B. Marangell, Biological Psychiatry Neuromodulation (Medicine)PsychiatryMood SymptomDepressionNaturalistic Study	2005	393
A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression Mark S. George, A. John Rush, Lauren B. Marangell, Biological Psychiatry One-year ComparisonStimulation DevicePain DisordersPsychiatryNeuromodulation Therapies	2005	369
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia Stephen K. Brannan, Sharon Sawchak, Andrew Miller, New England Journal of Medicine	2021	308
The Montgomery Äsberg and the Hamilton ratings of depression: A comparison of measures Thomas Carmody, A. John Rush, Ira H. Bernstein, European Neuropsychopharmacology Montgomery äSbergPsychiatryMood SymptomPsychologyDepression	2006	232
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial Inder Kaul, Sharon Sawchak, Christoph U. Correll, The Lancet Flexible-dose Phase 3PsychiatryPsychotic DisorderMedicinePsychopharmacology	2023	192
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder Stephen K. Brannan, Craig Mallinckrodt, Eileen B. Brown, Journal of Psychiatric Research PsychiatryPainful Physical SymptomsPain MedicinePsychotropic MedicationPharmacology	2004	180
Sexual Functioning Assessed in 4 Double-Blind Placebo- and Paroxetine-Controlled Trials of Duloxetine for Major Depressive Disorder Pedro L. Delgado, Stephen K. Brannan, Craig Mallinckrodt, The Journal of Clinical Psychiatry	2005	134

Page 1